MPN Workshop of the Carolinas 2025 | Addressing the unanswered questions and unmet needs that remain in the CMML space
In this video, Ami Patel, MD, Huntsman Cancer Institute, Salt Lake City, UT, briefly highlights some of the unanswered questions and unmet needs that remain in chronic myelomonocytic leukemia (CMML), with a focus on understanding the progression from a chronic to acute disease state and improving quality of life through targeting the myeloproliferative aspects of disease. This interview took place at the 2nd Annual MPN Workshop of the Carolinas, held in Charlotte, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So this is a big issue. So the overall survival for CMML patients is quite poor, only three years. And the average age of diagnosis is in the mid-70s, and so these patients are often not transplant candidates. What really drives a lot of the mortality is progression to acute myelomonocytic leukemia. And so kind of figuring out what drives that progression from a chronic disease state to an acute leukemia is really a big focus, a big research focus, of our laboratory...
So this is a big issue. So the overall survival for CMML patients is quite poor, only three years. And the average age of diagnosis is in the mid-70s, and so these patients are often not transplant candidates. What really drives a lot of the mortality is progression to acute myelomonocytic leukemia. And so kind of figuring out what drives that progression from a chronic disease state to an acute leukemia is really a big focus, a big research focus, of our laboratory. And then just kind of improving quality of life for these patients, because it is really quite a distinct disease from MDS, and it’s been historically lumped in with MDS. And so focusing more on the myeloproliferative aspects of disease that are tied to symptom improvement.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Genentech, Menarini-Stemline, Novartis.
